The invention relates to a pharmaceutical combination which comprises (a) a compound inhibiting BRAFV600E and (b) a compound which inhibits MerTK activation for simultaneous, separate or sequential use a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use and to a method of treatment of a warm-blooded animal, especially a human.
